For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the…
News
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed…
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma…
Following a three-year hiatus due to the COVID-19 pandemic, the Patient and Family Seminar hosted by the International Myeloma Foundation (IMF) will return…
Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with…
Huadong Medicine has been granted the exclusive rights in China to commercialize CT053, CARsgen Therapeutics’ investigational cell therapy for people with relapsed or…
In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib)…
Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the…
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory…
